BioVie (BIVI): רווח נקי למניה ב-12 החודשים האחרונים

BioVie Inc. (BIVI) relies on investment capital, as a stable cash flow from the development of cirrhosis drugs has not yet been established. Management is focused on identifying therapies for Alzheimer's disease and liver pathologies. Experienced management is conducting trials transparently, although the market value of assets is still being refined. The current trailing 12-month earnings per share illustrates the financial dynamics, and -2.89 shows the level of this metric.

Net income per share determines the proportion of equity in the company's total income. Calculating this over four quarters neutralizes differences between reporting standards, ensuring an objective valuation. By analyzing the trailing twelve-month earnings per share, an investor can see the real efficiency dynamics of the business. For BioVie Inc. (BIVI), this metric reflects financial stability during drug development. The non-cyclical nature of pharmaceuticals makes this indicator independent of economic crises.